View Post

Pfizer Gains Priority Review For Breast Cancer Drug, Can It Succeed?

In In The News by Barbara Jacoby

By: Terry Chrisomalis From: seekingalpha.com Summary Pfizer obtains priority review for talazoparib in treating patients with germline BRCA-mutated breast cancer, with FDA decision date by December 2018. Treatment with talazoparib in BRCA-mutated breast cancer reduced the risk of disease progression by 46%. If talazoparib is approved by the FDA it will have to go up against other competing drugs for the same …

500,000 denied 7p-a-day breast cancer drug

In In The News, Uncategorized by Barbara Jacoby

By: Sophie Borland From: dailymail.co.uk Nearly half a million women are being denied a 7p-a-day pill that could prevent breast cancer because of NHS red tape. Those with a family history of the  illness should be offered Tamoxifen or the similar drug Raloxifene, which can cut their risk by 40 per cent. The medicines watchdog NICE urged doctors to offer …

Will Pfizer Unveil A Breast Cancer Blockbuster This Sunday?

In In The News by Barbara Jacoby

By: Matthew Harper From: forbes.com A decade ago, Pfizer PFE +0.34%, then the world’s largest drug company, sold three of the 10 biggest-grossing medicines in the United States. Now, it doesn’t boast one. Wall Street analysts think a study of a breast cancer medicine being presented at a medical meeting in San Diego on Sunday could give the drug giant …

Two Experimental Breast-Cancer Drugs Pass Major Milestone in Study

In In The News by Barbara Jacoby

By Ron Winslow From: The Wall Street Journal Two experimental breast-cancer drugs passed a major milestone in a closely watched study that is part of a growing effort to revamp clinical trials and hasten the path of new medicines to the market. Researchers reported Friday that one of the drugs, AbbVie Inc.’s (ABBV) veliparib, proved especially promising against so-called triple …

New drug treats breast cancer

In In The News by Barbara Jacoby

The Walter And Eliza Hall Institute Breast cancer researchers Dr Delphine Merino, Dr François Vaillant, Professor Geoff Lindeman, Professor Jane Visvader and colleagues have shown that BH3-mimetic anti-cancer compounds were effective in treating aggressive breast cancers when combined with a conventional chemotherapy drug. Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could …